about
Steroidal Pyrimidines and Dihydrotriazines as Novel Classes of Anticancer Agents against Hormone-Dependent Breast Cancer Cells.Selective Estrogen Receptor Degraders (SERDs): A Promising Treatment to Overcome Resistance to Endocrine Therapy in ERα-Positive Breast Cancer.Phase I study of taselisib in Japanese patients with advanced solid tumors or hormone receptor-positive advanced breast cancer.Chemoprevention of LA7-Induced Mammary Tumor Growth by SM6Met, a Well-Characterized Cyclopia Extract.The efficacy and safety of targeted therapy plus fulvestrant in postmenopausal women with hormone-receptor positive advanced breast cancer: A meta-analysis of randomized-control trials
P2860
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
A Review of Fulvestrant in Breast Cancer.
@en
A Review of Fulvestrant in Breast Cancer.
@nl
type
label
A Review of Fulvestrant in Breast Cancer.
@en
A Review of Fulvestrant in Breast Cancer.
@nl
prefLabel
A Review of Fulvestrant in Breast Cancer.
@en
A Review of Fulvestrant in Breast Cancer.
@nl
P2860
P1433
P1476
A Review of Fulvestrant in Breast Cancer.
@en
P2093
Peter Schmid
P2860
P2888
P356
10.1007/S40487-017-0046-2
P577
2017-05-08T00:00:00Z